Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Terns Pharmaceuticals Inc TERN

Healthcare Biotechnology
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its pipeline includes three clinical-stage development programs: TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors... see more

Recent & Breaking News (NDAQ:TERN)

Terns Pharmaceuticals to Host Conference Call to Discuss Top-line Results from Phase 2a LIFT Study of TERN-101 for Treatment of NASH

GlobeNewswire June 13, 2021

Terns to Present at the UBS Global Healthcare Virtual Conference & Participate in the J.P. Morgan Biotech 2021 CEO Conference Call Series

GlobeNewswire May 19, 2021

Terns Reports First Quarter 2021 Financial Results and Provides Corporate Update

GlobeNewswire May 13, 2021

Terns to Present at the 19th Annual Virtual Needham HealthCare Conference

GlobeNewswire April 7, 2021

Terns Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

GlobeNewswire March 30, 2021

Terns Announces Initiation of Dosing in Phase 1 Clinical Trial of TERN-501, its THR-Beta Agonist in Development for the Treatment of NASH

GlobeNewswire March 22, 2021

Terns to Present on VAP-1 and FXR at NASH-TAG Conference 2021

GlobeNewswire March 8, 2021

Terns to Present at the Cowen 41st Annual Health Care Conference

GlobeNewswire February 23, 2021

Terns Pharmaceuticals, Inc. Announces Closing of Initial Public Offering and Exercise in Full of Underwriters' Option to Purchase Additional Shares

GlobeNewswire February 10, 2021

Terns Pharmaceuticals, Inc. Announces Pricing of Upsized Initial Public Offering of Common Stock

GlobeNewswire February 4, 2021